Matrixyl (Palmitoyl Pentapeptide-4): Research Guide & Chemical Profile

Matrixyl is the trade name for Palmitoyl Pentapeptide-4 (Pal-KTTKS), a synthetic lipopeptide consisting of the five-amino-acid sequence lysine-threonine-threonine-lysine-serine (KTTKS) conjugated at the N-terminus to palmitic acid (hexadecanoic acid, C16:0). The molecular formula is C39H75N7O10 with a molecular weight of approximately 802.05 Da. The KTTKS sequence corresponds to a fragment of the C-terminal propeptide domain of type I procollagen, specifically residues 1192-1196 of the pro-alpha1(I) chain.

The palmitoyl modification serves a critical function: it increases the lipophilicity of the parent pentapeptide, enhancing membrane permeability and cellular uptake. Without lipid conjugation, the hydrophilic KTTKS pentapeptide exhibits limited ability to cross biological membranes. The C16 fatty acid chain provides an optimal balance between enhanced penetration and maintained aqueous solubility when formulated appropriately. The peptide bond between palmitic acid and the epsilon-amino group of the N-terminal lysine residue creates a stable amide linkage resistant to simple hydrolysis under physiological conditions.

The CAS registry number for Pal-KTTKS is 214047-00-4. The compound is typically supplied as a white to off-white lyophilized powder with high hygroscopicity. In solution, it demonstrates pH-dependent solubility with optimal dissolution in slightly acidic to neutral aqueous buffers (pH 5.0-7.0). The isoelectric point of the peptide portion falls near pH 9.5 due to the two lysine residues contributing positive charges.

• Sequence: Pal-Lys-Thr-Thr-Lys-Ser (Pal-KTTKS)
• Molecular weight: ~802.05 Da
• Molecular formula: C39H75N7O10
• CAS number: 214047-00-4
• Origin: Type I procollagen C-propeptide fragment (residues 1192-1196)
• Lipid conjugate: Palmitic acid (C16:0) at N-terminal lysine
• Appearance: White to off-white lyophilized powder
• Solubility: Aqueous buffers pH 5.0-7.0; enhanced with mild surfactants

The biological activity of Pal-KTTKS is rooted in the physiological feedback mechanism governing collagen homeostasis. During normal collagen turnover, type I procollagen is cleaved at both N-terminal and C-terminal propeptide domains by specific proteinases (ADAMTS-2 and BMP-1 respectively) to yield mature collagen molecules that assemble into fibrils. The released C-propeptide fragments, including sequences encompassing KTTKS, act as positive feedback signals that stimulate new procollagen synthesis by dermal fibroblasts.

Research has demonstrated that Pal-KTTKS activates the transforming growth factor-beta (TGF-β) signaling pathway in human dermal fibroblasts. Specifically, the peptide promotes TGF-β1 expression and secretion, which subsequently signals through TGF-β type I and type II serine/threonine kinase receptors. Downstream, the canonical Smad2/3 phosphorylation cascade is activated, leading to nuclear translocation of the Smad2/3-Smad4 complex, which binds Smad-binding elements in the promoter regions of genes encoding type I collagen (COL1A1, COL1A2), type III collagen (COL3A1), and fibronectin.

Beyond the canonical Smad pathway, Pal-KTTKS engagement of TGF-β signaling also activates non-canonical pathways including p38 MAPK and JNK, which contribute to extracellular matrix gene expression through AP-1 transcription factor modulation. The peptide has also been shown to suppress matrix metalloproteinase (MMP) expression, particularly MMP-1 (interstitial collagenase) and MMP-3 (stromelysin-1), shifting the balance from matrix degradation toward matrix deposition. This dual mechanism of enhanced synthesis and reduced degradation amplifies the net effect on extracellular matrix accumulation.

The foundational research on KTTKS collagen-stimulating activity was published by Katayama et al. in 1993, who demonstrated that synthetic peptides derived from the type I procollagen C-propeptide could stimulate extracellular matrix production by human fibroblasts in culture. The pentapeptide KTTKS was identified as the minimal active sequence retaining significant biological activity within the larger propeptide fragment.

Subsequent studies by Robinson et al. (2005) using human dermal fibroblast monolayer cultures demonstrated that Pal-KTTKS at concentrations of 1-3 ppm significantly increased the production of types I, III, and IV collagen, as well as fibronectin, compared to vehicle-treated controls. Type I collagen production was increased by approximately 100-350% depending on concentration and culture conditions. The lipopeptide form consistently outperformed unconjugated KTTKS, confirming the importance of the palmitoyl modification for biological activity in cell-based assays.

In three-dimensional skin equivalent models (reconstructed human epidermis on dermal fibroblast-populated collagen lattices), Pal-KTTKS treatment increased dermal equivalent thickness and collagen fiber density as assessed by Masson trichrome staining and picrosirius red birefringence under polarized light microscopy. These organotypic models provide more physiologically relevant conditions than monolayer cultures, as the three-dimensional architecture and cell-matrix interactions more closely recapitulate the in vivo dermal environment.

The effects of Pal-KTTKS extend beyond collagen synthesis to broader extracellular matrix (ECM) remodeling. Research has shown upregulation of additional ECM components including elastin, hyaluronic acid (through increased hyaluronan synthase 2 expression), glycosaminoglycans, and various proteoglycans including decorin and versican. This comprehensive ECM response suggests activation of a coordinated matrix assembly program rather than isolated stimulation of a single protein.

The regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) is a critical aspect of Pal-KTTKS activity. Studies have demonstrated downregulation of MMP-1, MMP-2, MMP-3, and MMP-9 at both mRNA and protein levels, while TIMP-1 and TIMP-2 expression is maintained or upregulated. This shift in the MMP/TIMP balance reduces the rate of ECM degradation, complementing the stimulation of new matrix synthesis. The net result is increased ECM density and structural organization.

Gene expression profiling using microarray analysis of Pal-KTTKS-treated fibroblasts has revealed differential regulation of over 300 genes, with enrichment in functional categories including ECM organization, cell adhesion, cytoskeletal remodeling, and wound healing. Notable upregulated genes include LOXL2 (lysyl oxidase-like 2, involved in collagen cross-linking), ITGA2 (integrin alpha-2, a collagen receptor), and SPARC (secreted protein acidic and rich in cysteine, a matricellular protein involved in collagen fibril assembly).

Systematic structure-activity relationship (SAR) studies have dissected the contributions of individual residues and structural features to the biological activity of Pal-KTTKS. Alanine scanning mutagenesis, where each residue is individually replaced by alanine, demonstrated that the two threonine residues (positions 2 and 3) and the C-terminal serine are most critical for collagen-stimulating activity, likely because their hydroxyl side chains participate in hydrogen bonding interactions essential for receptor or binding partner engagement.

The N-terminal lysine residue serves primarily as the lipid conjugation site, with activity maintained when replaced by ornithine (shorter side chain) or diaminobutyric acid. The C-terminal lysine at position 4 contributes to activity but is more tolerant of substitution than the central threonines. D-amino acid substitutions at any position dramatically reduce activity, confirming that the natural L-configuration is required for biological recognition.

Exploration of alternative lipid conjugates has revealed that the fatty acid chain length significantly influences activity. Chains shorter than C12 (lauroyl) show reduced activity correlating with decreased membrane interaction, while chains longer than C18 (stearoyl) reduce aqueous solubility without proportional activity gains. The C16 palmitoyl conjugate represents the empirically determined optimum. Branched-chain and unsaturated fatty acid conjugates have also been tested, with oleic acid (C18:1) conjugation showing comparable activity to palmitic acid.

A central challenge in Pal-KTTKS research is achieving sufficient delivery to the dermal compartment where target fibroblasts reside. Franz diffusion cell studies using excised human skin have shown that Pal-KTTKS penetration from simple aqueous solutions is limited, with the majority of applied peptide retained in the stratum corneum and only a small fraction (<2%) reaching the viable epidermis and dermis within 24 hours. The palmitoyl moiety, while enhancing membrane interaction, contributes to stratum corneum retention.

Various delivery systems have been investigated to enhance dermal penetration. Liposomal encapsulation (both conventional and deformable liposomes/transfersomes) increased dermal delivery by 3-5 fold compared to aqueous solution. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) provided sustained release profiles with enhanced dermal targeting. Microemulsion systems showed the highest enhancement ratios (up to 8-fold) due to the combined effects of surfactant-mediated penetration enhancement and the thermodynamic activity of the peptide in the vehicle.

More advanced approaches including dissolving microneedle arrays loaded with Pal-KTTKS have demonstrated direct dermal delivery bypassing the stratum corneum barrier entirely. Iontophoresis and sonophoresis-assisted delivery have also been explored with varying degrees of success. The choice of delivery strategy significantly impacts the effective concentration reaching dermal fibroblasts and consequently the magnitude of the biological response observed in experimental models.

Research has investigated combinations of Pal-KTTKS with other bioactive peptides targeting complementary mechanisms. The combination with Pal-GHK (palmitoyl tripeptide-1, a copper-binding peptide sequence) has been studied extensively, as these two peptides address different aspects of ECM homeostasis. Pal-GHK promotes ECM remodeling through activation of metalloproteinase-mediated turnover followed by new matrix synthesis, while Pal-KTTKS directly stimulates de novo collagen production. The combination (marketed as Matrixyl 3000) demonstrated additive or synergistic effects on type I collagen production in fibroblast cultures.

Combinations with SNAP-8 (acetyl octapeptide-3, a SNARE complex modulator) and acetyl hexapeptide-3 (Argireline) have been investigated for multi-target approaches. Since these peptides act through entirely different mechanisms (neuromuscular modulation versus ECM stimulation), they represent non-overlapping strategies. In vitro studies suggest that combining Pal-KTTKS with neuromuscular-targeting peptides does not result in antagonistic interactions, supporting the feasibility of multi-peptide formulation strategies.

Antioxidant peptide combinations have also shown promise. Co-treatment of Pal-KTTKS with carnosine or glutathione-related peptides enhanced the protective effect against oxidative stress-induced MMP upregulation in fibroblasts, suggesting that antioxidant co-treatment may preserve the ECM-building effects of Pal-KTTKS under conditions of oxidative challenge that would otherwise shift the balance toward matrix degradation.

Analytical characterization of Pal-KTTKS requires methods capable of handling both the hydrophilic peptide portion and the lipophilic palmitoyl chain. Reversed-phase HPLC (RP-HPLC) using C18 columns with gradient elution from aqueous trifluoroacetic acid to acetonitrile is the standard chromatographic method for identity and purity assessment. The lipopeptide elutes at relatively high organic solvent concentrations (typically 70-80% acetonitrile) due to the hydrophobic palmitoyl chain, distinguishing it from unconjugated KTTKS which elutes much earlier.

Mass spectrometric confirmation is performed by ESI-MS or MALDI-TOF MS, with the expected [M+H]+ ion at m/z 803.06 and characteristic fragmentation pattern in MS/MS analysis. Key fragment ions correspond to sequential loss of amino acid residues from the C-terminus and loss of the palmitoyl chain (m/z 563.3 for the KTTKS fragment). LC-MS/MS methods provide both identification and quantification with limits of detection in the low ng/mL range, suitable for penetration studies and formulation analysis.

Stability-indicating methods must discriminate the intact lipopeptide from degradation products including free KTTKS (hydrolysis of the palmitoyl-lysine amide bond), des-serine tetrapeptide (C-terminal degradation), and oxidized variants (methionine-free but threonine dehydration products possible under harsh conditions). Forced degradation studies under acidic, basic, oxidative, thermal, and photolytic conditions establish the specificity of analytical methods for stability programs.

Pal-KTTKS demonstrates good chemical stability when stored as a lyophilized powder at -20°C under inert atmosphere (nitrogen or argon), with no significant degradation observed over 24 months. In aqueous solution, stability is pH-dependent: the peptide is most stable in the pH 4.0-6.0 range, with accelerated hydrolysis of the palmitoyl-lysine amide bond under strongly acidic (pH <3) or basic (pH >8) conditions. The half-life in phosphate-buffered saline at pH 7.4 and 25°C is approximately 6 months.

Formulation challenges include the amphiphilic nature of the molecule, which leads to surface adsorption on glass and certain plastic containers, micelle formation above a critical micelle concentration (CMC approximately 0.05 mM), and potential aggregation behavior. Inclusion of appropriate surfactants (polysorbate 20 or 80 at 0.01-0.1%) minimizes surface adsorption without interfering with biological activity. Buffer selection affects both stability and activity, with acetate buffers (pH 5.0-5.5) providing optimal stability characteristics.

For research applications requiring long-term storage of stock solutions, aliquoting into single-use volumes and storage at -80°C in siliconized or low-binding polypropylene tubes is recommended. Repeated freeze-thaw cycles should be limited to fewer than five, as surface adsorption losses accumulate with each cycle. Working concentrations should be prepared fresh from frozen stocks on the day of experimental use to ensure consistent dosing.

The following publications represent key research on Palmitoyl Pentapeptide-4 (Matrixyl) across its major investigational areas. Researchers are directed to these primary sources for experimental protocols and detailed data.

• Read more: TRH (Thyrotropin-Releasing Hormone): Research Guide & Chemical Profile → https://www.chemverify.com/learn/trh-thyrotropin-releasing-hormone-research-guide
• Read more: Ipamorelin + CJC-1295 (No DAC) Stack: Synergy Research Guide → https://www.chemverify.com/learn/ipamorelin-cjc-1295-no-dac-stack-synergy
• Read more: TP508 (Chrysalin): Research Guide & Chemical Profile → https://www.chemverify.com/learn/tp508-chrysalin-research-guide-chemical-profile
• Read more: Semax for Cognitive Research: ACTH(4-10) Analog Mechanism → https://www.chemverify.com/learn/semax-cognitive-research-acth-mechanism